EP0041766A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
New plasminogen activator and pharmaceutical composition having thrombolytic activity
Assignee: KU Leuven
•
Filing: 1981-06-10
•
Granted: —
•
Expires: 2001-06-10
Abstract
Abstract A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melamona cells. This new plasminogen activator has a strong thrombolytic effect and pharmaceutical compositions thereof may be used in the therapeutic treatment of thrombosis disorders.
Inventors
- 👤 Désiré J. Collen
- 👤 Dingeman C. Rijken
- 👤 Osamu Matsuo
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 04:10
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6459; A; A61; A61P; A61P7/00; A61P7/02; C12N1/00; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; A61K; A61K38/00; C12R; C12R2001/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/828
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
7 words
A plasminogen activator from human melanoma cells.
Claim 2
Dependent Claim
7 words
A plasminogen activator from human melanoma cells.
Claim 3
Dependent Claim
55 words
The plasminogen activator as claimed in claim 1, characterised by molecular weight of about 72,000 in unreduced form, determined with SDS-polyacrylamide gel electrophoresis, and by two bands having molecular weights of about 33,000 and about 39,000 resp. in reduced form, also determined by SDS-polyacrylamide gel electrophoresis, said activator showing a strong binding capacity to fibrin.
Claim 4
Dependent Claim
16 words
The plasminogen activator of claim 1, characterised by an amino acid composition according to table 1.
Claim 5
Dependent Claim
44 words
The plasminogen activator as claimed in claim 1, characterised by a molecular weight of about 72,000 in unreduced form and a molecular weight of about 72,000 in reduced form, both determined by SDS-polyacrylamide gel electrophoresis, said activator showing a strong binding capacity to fibrin.
Claim 6
Dependent Claim
16 words
The plasminogen activator of claim 1, characterised by an amino acid composition according to table 3.
Claim 7
Independent Claim
39 words
A method of preparing a plasminogen activator as claimed in claims 1-5, characterised by cultivating human melanoma cells in a suitable growth medium, followed by recovering the culture fluid which contains a plasminogen activator and purifying the resulting fluid.
Claim 8
Dependent Claim
30 words
The method of claim 6, characterised by performing the cultivation of melanoma cells in a conventional growth medium and by purifying the resulting fluid with a conventional protein purification method.
Claim 9
Dependent Claim
26 words
The method of claim 7, characterised by cultivating the melanoma cells in a modified Eagle's medium supplemented with sodium bicarbonate, L-glutamine and heat-inactivated fresh-born calf serum.
Claim 10
Dependent Claim
21 words
The method of claim 7, characterised by effecting the purification of the resulting fluid with the aid of ligand exchange chromatography.
Claim 11
Dependent Claim
18 words
The method of claim 9, characterised by using therein a metal chelate of agarose as a stationary phase.
Claim 12
Dependent Claim
16 words
The method of claim 10, characterised by effecting the ligand exchange chromatography on zinc chelate agarose.
Claim 13
Dependent Claim
12 words
The method of claim 7, characterised by effecting purification with affinity chromatography.
Claim 14
Dependent Claim
13 words
The method of claim 12, characterised by effecting affinity chromatography on lecting agarose.
Claim 15
Dependent Claim
21 words
The method of claim 7, characterised in that the purification is effected by gel filtration, preferably on a partially purified product.
Claim 16
Dependent Claim
16 words
The method of claim 14, characterised in that gel filtration is effected on cross-linked dextran particles.
Claim 17
Dependent Claim
20 words
The method of claim 5, characterised in that a non-ionic detergent is added to all buffer solutions used during purification.
Claim 18
Dependent Claim
18 words
The method of claim 5, characterised in that cultivation and purification are performed in the presence of aprotinin.
Claim 19
Dependent Claim
18 words
A pharmaceutical composition having thrombolytic activity and containing an effective amount of plasminogen activator according to claims 1-3.
Claim 20
Independent Claim
29 words
A method of preparing a pharmaceutical composition having thrombolytic acitvity, characterised by rendering a plasminogen activator as claimed in claims 1-3 to an administration form suitable for therapeutic utilisation.
Claim 21
Dependent Claim
27 words
A method for therapeutic treatment of thrombosis disorders, characterised by administering a therapeutically effective dose of a pharmaceutical composition as claimed in claim 18 to a pattient.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.